ArticleFrontiers in oncology2026
Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous group of malignancies with limited prospective data to guide systemic therapy. Immune-based combination regimens are increasingly used in this setting by extrapolation from clear cell RCC trials. Whether patient sex influences outcomes in metastatic nccRCC treated with first-line immunotherapy (IO)-based combinations remains unknown. Methods: This is a retrospective sub-analysis of the ARON-1 real-world study that included 256 patients with intermediate- or poor-risk metastatic nccRCC treated with first-line IO-based combinations across 56 centers in 17 countries between January 2021 and December 2024. Patients with favorable-risk disease were excluded. The primary objective was to compare overall survival (OS) and time on treatment (ToT) between male and female patients. Tumor responses were assessed per RECIST 1.1 criteria. Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazards regression models were used for univariable and multivariable analyses. Results: Of 256 patients included, 197 (77%) were male and 59 (23%) were female. The median OS in the overall population was 27.8 months (95% CI 22.6-36.5), with a 1-year OS rate of 80%. No statistically significant difference in OS was observed between females and males (31.9 months vs 26.7 months; p = 0.124). In the intermediate-risk subgroup, females demonstrated a longer median OS compared with males (36.1 vs. 27.8 months; HR 0.60; p = 0.041). Among patients with liver metastases, median OS was not reached in females versus 15.0 months in males (1-year OS: 88% vs. 53%; p < 0.001). In patients with papillary histology, females showed a significantly longer OS than males (36.1 vs. 27.8 months; HR 0.52; p = 0.037). Conclusions: In this large real-world study of IO-based combinations in metastatic nccRCC, no statistically significant sex-based difference in OS was observed in the overall population. Exploratory subgroup analyses identified potential sex-based interactions in intermediate-risk disease, liver metastases, and papillary histology that warrant prospective investigation. The underrepresentation of women in this cohort and the retrospective design underscore the need for dedicated, sex-stratified analyses in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.